JPWO2020006233A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020006233A5 JPWO2020006233A5 JP2020571855A JP2020571855A JPWO2020006233A5 JP WO2020006233 A5 JPWO2020006233 A5 JP WO2020006233A5 JP 2020571855 A JP2020571855 A JP 2020571855A JP 2020571855 A JP2020571855 A JP 2020571855A JP WO2020006233 A5 JPWO2020006233 A5 JP WO2020006233A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 230000001594 aberrant effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 230000004952 protein activity Effects 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023126807A JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692176P | 2018-06-29 | 2018-06-29 | |
| US62/692,176 | 2018-06-29 | ||
| PCT/US2019/039509 WO2020006233A1 (en) | 2018-06-29 | 2019-06-27 | Immunomodulatory compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126807A Division JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021530453A JP2021530453A (ja) | 2021-11-11 |
| JP2021530453A5 JP2021530453A5 (https=) | 2022-07-05 |
| JPWO2020006233A5 true JPWO2020006233A5 (https=) | 2022-07-05 |
| JP7328263B2 JP7328263B2 (ja) | 2023-08-16 |
Family
ID=68987232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571855A Active JP7328263B2 (ja) | 2018-06-29 | 2019-06-27 | 免疫調節化合物 |
| JP2023126807A Pending JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126807A Pending JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12234220B2 (https=) |
| EP (1) | EP3814330A4 (https=) |
| JP (2) | JP7328263B2 (https=) |
| KR (1) | KR102834593B1 (https=) |
| CN (1) | CN113166100A (https=) |
| AU (1) | AU2019293235B2 (https=) |
| CA (1) | CA3102212A1 (https=) |
| WO (1) | WO2020006233A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CA3102212A1 (en) * | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| CN120172958A (zh) | 2019-04-12 | 2025-06-20 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| AU2020392427B2 (en) * | 2019-11-27 | 2024-03-07 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| JP7682181B2 (ja) | 2019-12-18 | 2025-05-23 | ノバルティス アーゲー | ３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2022255889A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| PY2243958A (es) | 2021-06-03 | 2023-01-20 | Novartis Ag | Derivados de 3–(5–oxi)–1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos |
| CN120303264A (zh) | 2022-09-09 | 2025-07-11 | 医诺康治疗公司 | CK1α和双重CK1α/GSPT1降解化合物 |
| CN116655595A (zh) * | 2023-06-05 | 2023-08-29 | 中国人民解放军军事科学院军事医学研究院 | 2,6-哌啶二酮衍生物及其制备和用途 |
| WO2025063888A1 (en) | 2023-09-19 | 2025-03-27 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| WO2008007979A1 (en) * | 2006-07-12 | 2008-01-17 | Auckland Uniservices Limited | (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives |
| US11395820B2 (en) * | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
| CN109790143A (zh) * | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| BR112019015484A2 (pt) * | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CA3102212A1 (en) * | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
-
2019
- 2019-06-27 CA CA3102212A patent/CA3102212A1/en active Pending
- 2019-06-27 AU AU2019293235A patent/AU2019293235B2/en active Active
- 2019-06-27 EP EP19826640.5A patent/EP3814330A4/en active Pending
- 2019-06-27 KR KR1020217002635A patent/KR102834593B1/ko active Active
- 2019-06-27 US US17/255,738 patent/US12234220B2/en active Active
- 2019-06-27 CN CN201980056905.1A patent/CN113166100A/zh active Pending
- 2019-06-27 JP JP2020571855A patent/JP7328263B2/ja active Active
- 2019-06-27 WO PCT/US2019/039509 patent/WO2020006233A1/en not_active Ceased
-
2023
- 2023-08-03 JP JP2023126807A patent/JP2023145694A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530453A5 (https=) | ||
| JP2021530451A5 (https=) | ||
| US20230270698A1 (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| JPWO2020006233A5 (https=) | ||
| JP2021191784A5 (https=) | ||
| JPWO2022002237A5 (https=) | ||
| RU2017143776A (ru) | Пролекарства альвоцидиба, имеющие повышенную биодоступность | |
| JP2021535147A5 (https=) | ||
| JP2017510610A5 (https=) | ||
| JP2025060958A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2021530487A5 (https=) | ||
| JP2020534270A5 (https=) | ||
| JP2020510085A5 (https=) | ||
| CN111727059A (zh) | 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法 | |
| JP2022169780A5 (https=) | ||
| JP2019524888A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| JPWO2022059692A5 (https=) | ||
| JP2017514829A5 (https=) | ||
| JPWO2023064282A5 (https=) | ||
| EP4026544A1 (en) | Pharmaceutical composition comprising hdac inhibitor and anti-pd1 antibody or anti pd-l1 antibody | |
| JPWO2022192781A5 (https=) | ||
| JPWO2023163203A5 (https=) | ||
| JPWO2023129909A5 (https=) |